DiagnoCure acquires new high-value diagnostic tests for breast and colon cancer

    - Company Acquires Catalyst Oncology of Worcester, MA -
    - Announces conference call to update investors -

    Ticker Symbol: CUR

    QUEBEC CITY, Aug. 16 /CNW/ - DiagnoCure (TSX: CUR), a life sciences
company commercializing high-value cancer diagnostic tests and delivering lab
services, today announced it has acquired Catalyst Oncology of Worcester, MA,
and its lead proprietary prognostic tests for breast, colon and potentially
other cancers. DiagnoCure intends to complete the development of the tests and
conduct additional validating clinical studies.
    "This acquisition reflects the continuing execution of our focused M&A
strategy, aimed at building a critical mass of high-value oncology diagnostic
products that will be offered through our U.S. CLIA-certified laboratory,
which is on track to open later this year," said John Schafer, President and
CEO of DiagnoCure. "The newly acquired tests have the potential to increase
clinician and patient confidence when making critical treatment decisions and
will complement our GC-C-based tests for colorectal cancer, acquired earlier
this year."
    The acquired tests have been validated in multiple clinical studies
involving patients with five tumor types, including breast and colon. Results
have shown the tests to be strong indicators for a patient's risk of disease
recurrence, as well as predictors of response to certain cancer therapies,
such as tamoxifen or traditional chemotherapy. The tests measure the level of
activated tyrosine phosphorylated (PY) Shc protein and p66 Shc protein in
tissue specimens. The Shc proteins are involved in a number of well documented
 cellular pathways that are correlated with tumor aggressiveness across many
types of cancer, offering a broad opportunity for clinical testing. These
tests were developed by A. Raymond Frackelton Jr., Ph.D., and researchers at
the Roger Williams Medical Center of Providence, Rhode Island.
    With a 2007 estimate of 178,480 new cases and 40,460 deaths in the United
States, breast cancer is the most frequently diagnosed cancer and the second
leading cause of death from cancer in women. The global survival rate over
five years is 89% but falls to 26% when breast cancer has spread to distant
organs. Appropriate risk assessment of the cancer after the initial treatment
will facilitate critical treatment decisions and may increase the probability
of recurrence-free survival, while avoiding ineffective treatments and related
    The terms of the agreement call for an upfront payment of approximately
US$3 million comprised of cash and DiagnoCure shares followed by potential
future payments related to the achievement of specific milestones.

    Conference call Thursday

    Mr. Schafer and members of his management team will talk with investors
via conference call Thursday, August 16, 2007, at 10:30 AM Eastern Daylight
time. To access the audio conference in real-time, please dial 1-800-731-6941.
A replay of the audio conference will also be available on DiagnoCure's
website at www.diagnocure.com as of August 17, 2007, at 12:00 p.m. (ET),
through a link on our Investors page.

    About DiagnoCure

    DiagnoCure (TSX: CUR) is a life sciences company commercializing
high-value cancer diagnostic tests and delivering lab services that increase
clinician and patient confidence in making critical treatment decisions.
DiagnoCure is currently preparing to launch the first GC-C-based molecular
test for the management of colorectal cancer. In 2003, the Company entered
into a strategic alliance with Gen-Probe (NASDAQ:   GPRO) for the development
and commercialization of a second-generation test for PCA3, DiagnoCure's
proprietary genetic marker highly specific to prostate cancer. The test is now
available through laboratories in the U.S. using PCA3 analyte specific
reagents (ASR) from Gen-Probe, and in Europe as the CE-marked PROGENSA(TM)
PCA3 in vitro assay. In addition to its own research, the Company intends to
acquire or in-license additional promising cancer biomarkers from both
academic and commercial institutions. For more information visit

    Forward-looking statements

    This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects, clinical studies and future
revenues are based on management expectations. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading "Risk
Factors". DiagnoCure undertakes no obligation to publicly update or revise any
forward-looking statements contained herein.

    %SEDAR: 00003671EF

For further information:

For further information: DiagnoCure Inc., Thom Skinner, Chief Financial
Officer, (418) 527-6100, communications@diagnocure.com; The Equicom Group
Inc., Eric Bouchard, (514) 844-7997, ebouchard@equicomgroup.com

Organization Profile

DiagnoCure Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890